Metachromatic Leukodystrophy (Mld) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Metachromatic leukodystrophy (MLD) is a rare, autosomal recessive lysosomal storage disorder caused by deficiency of the enzyme arylsulfatase A (ASA), encoded by the [ARSA gene[/genes/[arsa[/genes/[arsa[/genes/[arsa--TEMP--/genes)--FIX-- on chromosome 22q13.31. The resulting accumulation of sulfatides (galactosyl-3-O-sulfocerebroside) — essential components of myelin — leads to progressive demyelination of both the central and peripheral nervous systems. MLD belongs to the sphingolipidoses, a subgroup of sphingolipid metabolism disorders, and represents one of the most devastating inherited leukodystrophies.
The disease is classified by age of onset into late-infantile (the most severe form), early-juvenile, late-juvenile, and adult subtypes. MLD affects an estimated 1 in 40,000 to
160,000 live births worldwide [11] has transformed the
treatment landscape for presymptomatic and early-symptomatic patients, though it remains one of the most expensive therapies ever developed.
- Incidence: Estimated at 0.16–1.85 per 100,000 live births depending on population. Overall incidence approximately 1 in 40,000–160,000 births.
- Subtype distribution: [Late[/diseases/[late[/diseases/[late[/diseases/[late--TEMP--/diseases)--FIX---infantile MLD accounts for approximately 50–60% of cases; juvenile forms ~20–30%; adult MLD ~15–20%.
- Children: Account for ~70% of all cases; most become progressively disabled, with death occurring within 5–10 years of symptom onset in infantile forms.
- Geographic variation: Higher prevalence in certain populations including Habbanite Jews (1):75), western Navajo, and some populations in the Middle East and South Asia.
- Carrier frequency: Estimated at 1:100 in the general population.
¶ Genetics and Molecular Basis
The vast majority (~95%) of MLD cases result from biallelic pathogenic variants in the ARSA gene (22q13.31), encoding arylsulfatase A (also called cerebroside-3-sulfatase).
Over 250 pathogenic variants have been identified [8], including missense, nonsense, splice-site mutations, and small deletions. Key genotype-phenotype correlations
include A** (splice site mutation; null allele; ~25% of European alleles)
- p.Pro426Leu (missense; residual activity allele; ~20% of European alleles)
ASA pseudodeficiency (PD alleles) reduces ASA activity to 5–20% of normal but does not cause MLD. Pseudodeficiency alleles are common (1–2% of the general population) and complicate biochemical diagnosis. Combined heterozygosity for a pathogenic allele and a PD allele can create diagnostic confusion, requiring molecular confirmation.
A rare variant of MLD (~1–5% of cases) results from mutations in the PSAP gene (10q21-22), encoding prosaposin, the precursor of saposin B. Saposin B is a sphingolipid activator protein required for ASA to access sulfatide substrates within lysosomes. Without saposin B, sulfatide catabolism is impaired despite normal ASA protein levels. The clinical presentation is indistinguishable from ARSA-deficient MLD but requires distinct diagnostic approaches (normal ASA activity with elevated sulfatides).
¶ Sulfatide Accumulation and Demyelination
ASA deficiency leads to progressive accumulation of sulfatides (galactosyl-3-O-sulfocerebroside) in [oligodendrocytes[/cell-types/[oligodendrocytes[/cell-types/[oligodendrocytes[/cell-types/[oligodendrocytes--TEMP--/cell-types)--FIX-- (CNS) and [Schwann cells[/cell-types/[schwann-cells[/cell-types/[schwann-cells[/cell-types/[schwann-cells--TEMP--/cell-types)--FIX-- (PNS). Sulfatides are essential structural components of the myelin sheath [9]
- Lysosomal overload: Intralysosomal sulfatide storage leads to [lysosomal dysfunction[/mechanisms/[lysosomal-dysfunction[/mechanisms/[lysosomal-dysfunction[/mechanisms/[lysosomal-dysfunction--TEMP--/mechanisms)--FIX--, impaired [autophagy[/entities/[autophagy[/entities/[autophagy[/entities/[autophagy--TEMP--/entities)--FIX--, and progressive organelle damage
- Membrane destabilization: Excess sulfatides disrupt myelin membrane stability, leading to myelin breakdown and widespread [demyelination[/mechanisms/[demyelination[/mechanisms/[demyelination[/mechanisms/[demyelination--TEMP--/mechanisms)--FIX--
- Inflammatory activation: Released sulfatides activate [microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia--TEMP--/cell-types)--FIX--
The most common and severe form. After an initial period of normal development, children present with:
-
Motor regression: Progressive gait deterioration, frequent falls, loss of independent ambulation (typically by age 3–4)
-
Peripheral neuropathy: Areflexia, reduced nerve conduction velocities
-
Cognitive decline: Language regression, behavioral changes
-
Rapid progression: Loss of all motor and cognitive function; death typically within 2–5 years of onset (mean life expectancy ~4 years after diagnosis) 16 years)
-
Often misdiagnosed as psychiatric illness (schizophrenia, depression, bipolar disorder) for months to years before neurological features emerge
-
Psychiatric symptoms: personality changes, psychosis, cognitive decline, executive dysfunction
-
Gradual motor deterioration: gait difficulty, spasticity, extrapyramidal features
-
Peripheral neuropathy is common
-
Most variable course: some patients survive >20 years from symptom onset
- ASA enzyme activity: Measured in leukocytes or fibroblasts; deficient in ARSA-MLD. Note: ASA pseudodeficiency can complicate interpretation (5–20% activity without disease).
- Urinary sulfatides: Elevated in MLD; quantitative analysis by mass spectrometry is more specific than qualitative testing.
- Sulfatide loading assay: Cultured fibroblasts tested for sulfatide degradation capacity; distinguishes pathogenic from pseudodeficiency alleles.
- ARSA gene sequencing: Confirms diagnosis and enables genotype-phenotype correlation.
- PSAP gene testing: When ASA activity is normal but sulfatides are elevated (suspected saposin B deficiency).
- Family screening and carrier testing: Critical for genetic counseling and identifying presymptomatic siblings who may benefit from early gene therapy.
- Newborn screening: Pilot programs underway using sulfatide quantification in dried blood spots, critical for enabling pre-symptomatic treatment with gene therapy [11].
- AAV-based approaches: Intrathecal/intracranial delivery of AAV vectors (AAV9, novel capsid AAV.GMU01) encoding ARSA, enabling direct CNS transduction without myeloablative conditioning. Phase I/II clinical trials are underway [6]
- Combined approaches: AAV gene therapy plus enzyme replacement or substrate reduction therapy under investigation for synergistic benefit.
- Allogeneic HSCT from HLA-matched donors can stabilize or slow progression in juvenile and adult MLD if performed before significant neurological deterioration.
- Less effective in late-infantile MLD due to the time required for donor cell engraftment and microglial replacement (6–12 months) relative to rapid disease progression.
- Risks include graft-versus-host disease, graft failure, and transplant-related mortality.
- Being replaced by gene therapy where available, though HSCT remains an option when gene therapy is not accessible.
- Physical therapy for spasticity management and contracture prevention
- Speech therapy and alternative communication devices
- Nutritional support (gastrostomy tube when dysphagia develops)
- Seizure management with anticonvulsants
- Pain management for neuropathic pain
- Respiratory support in advanced disease
- Psychosocial support for families
Prognosis varies significantly by subtype:
- Late-infantile MLD: Most severe; median survival ~5 years from onset without treatment
- Juvenile MLD: Intermediate; survival typically 10–20 years from onset
- Adult MLD: Most variable; some patients survive >20 years, though progressive disability is inevitable without treatment
- With gene therapy: Presymptomatic treatment can preserve normal or near-normal development, fundamentally altering the natural history. Long-term data (>5 years) continue to show sustained benefit.
- [Oligodendrocytes[/cell-types/[oligodendrocytes[/cell-types/[oligodendrocytes[/cell-types/[oligodendrocytes--TEMP--/cell-types)--FIX--
- [Schwann Cells[/cell-types/[schwann-cells[/cell-types/[schwann-cells[/cell-types/[schwann-cells--TEMP--/cell-types)--FIX--
- [Neurodegenerative Diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/diseases
- [Antisense Oligonucleotide (ASO) Therapy in Neurodegeneration[/treatments/[antisense-oligonucleotide-therapy[/treatments/[antisense-oligonucleotide-therapy[/treatments/[antisense-oligonucleotide-therapy--TEMP--/treatments)--FIX--
- [Gene Therapy for Neurodegenerative Diseases[/treatments/[gene-therapy[/treatments/[gene-therapy[/treatments/[gene-therapy--TEMP--/treatments)--FIX--
The study of Metachromatic Leukodystrophy (Mld) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying [mechanisms of neurodegeneration[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/mechanisms and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- [Gieselmann V, Krägeloh-Mann I. Metachromatic leukodystrophy — an update. Neuropediatrics. 2010;41(1):1-6. DOI
- [van Rappard DF, Boelens JJ, Wolf NI. Metachromatic leukodystrophy: disease spectrum and approaches for treatment. Best Pract Res Clin Endocrinol Metab. 2015;29(2):261-273. DOI
- [Biffi A, et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science. 2013;341(6148):1233158. DOI
- [Fumagalli F, et al. Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1/2 trial and expanded access. Lancet. 2022;399(10322):372-383. DOI
- [Kehrer C, et al. The natural course of gross motor deterioration in metachromatic leukodystrophy. Dev Med Child Neurol. 2011;53(9):850-855. DOI
- [Rosenberg JB, et al. Cross-species efficacy of AAV-mediated ARSA replacement for metachromatic leukodystrophy. Mol Ther. 2025. DOI
- [Patil SA, Maegawa GH. Developing therapeutic approaches for metachromatic leukodystrophy. Drug Des Devel Ther. 2013;7:729-745. DOI
- [Cesani M, et al. Mutation update of ARSA and PSAP [genes[/[genes[/[genes[/[genes[/[genes[/[genes[/[genes[/genes causing metachromatic leukodystrophy. Hum Mutat. 2016;37(1):16-27. DOI
- [Berger J, Gieselmann V, Matzner U. The roles of sulfatide in the nervous system. Neurochem Res. 2023;48(11):3382-3401. DOI
- [Groeschel S, et al. Metachromatic leukodystrophy: natural course of cerebral MRI changes in relation to clinical course. J Inherit Metab Dis. 2011;34(5):1095-1102. DOI
- FDA approves first gene therapy for metachromatic leukodystrophy (March 18, 2024)
- [Elgün S, et al. Consensus guidelines for the monitoring and management of metachromatic leukodystrophy in the United States. Cytotherapy. 2024. DOI